CareDx Unveils Strategic Expansion of Transplant+ Platform and AlloHeme Development Timeline Ahead of 2026 Milestones

CareDx announced a phased rollout of its Transplant+ platform, targeting full integration across 150 transplant centers by the end of 2025, with an initial deployment in 60 centers already underway. The platform is designed to consolidate post-transplant monitoring through a suite of non-invasive tests, including cell-free DNA analysis and biomarker profiling, aiming to reduce biopsy dependency by 40% in clinical settings. The company confirmed that AlloHeme, its novel hemoglobin-based oxygen therapeutic, is progressing through Phase 2 clinical trials with a primary endpoint readout expected in Q3 2025. Enrollment has reached 120 patients across 18 U.S. and European sites, with interim data showing a 25% improvement in oxygen delivery metrics compared to standard care in acute anemia scenarios. A pivotal Phase 3 trial is scheduled to begin in early 2026, contingent on regulatory feedback. CareDx also outlined a 2026 financial outlook, projecting $185 million in revenue, driven by a 30% year-over-year increase in Transplant+ subscription revenues and potential early commercialization in Japan and Germany. The company expects to achieve cash flow breakeven by Q4 2026, supported by $40 million in anticipated milestone payments from strategic partnerships. Market analysts noted the company's expanded diagnostic portfolio and AlloHeme’s potential to address unmet needs in critical care, particularly in perioperative and trauma settings. The announcement led to a 9.2% intraday rise in CareDx’s stock, reflecting investor confidence in its diversified pipeline and execution capability.